Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Transaction in Own Shares

12th Jan 2026 07:00

RNS Number : 4115O
CVS Group plc
12 January 2026
 

12 January 2026

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

 

CVS announces that on 09 January 2026 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

 

Date of purchase:

09/01/2026

Aggregate number of Ordinary Shares purchased:

30,119

Lowest price paid per share (GBp):

1,324.00

Highest price paid per share (GBp):

1,360.00

Volume weighted average price paid per share (GBp):

1,344.63

CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,551,512 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 70,551,512 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has repurchased 1,189,271 Ordinary Shares in aggregate at a weighted average price of 1,231.92 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

 

Individual transactions:

 

Number of

Ordinary Shares purchased

Transaction price (GBp share)

Time of

transaction (UK Time)

Transaction

reference number

Trading Venue

 

231

1324

09/01/2026 08:08:13

1367544040526662

XLON

66

1324

09/01/2026 08:09:54

1367544040527466

XLON

553

1330

09/01/2026 08:12:24

1367544040527993

XLON

600

1330

09/01/2026 08:19:13

1367544040529841

XLON

387

1330

09/01/2026 08:27:43

1367544040531501

XLON

49

1330

09/01/2026 08:27:43

1367544040531502

XLON

320

1330

09/01/2026 08:27:44

1367544040531519

XLON

797

1338

09/01/2026 08:52:39

1367544040534919

XLON

1390

1338

09/01/2026 08:52:47

1367544040534928

XLON

1390

1338

09/01/2026 08:58:18

1367544040535665

XLON

725

1338

09/01/2026 08:59:31

1367544040535843

XLON

148

1340

09/01/2026 09:04:38

1367544040537216

XLON

1158

1338

09/01/2026 09:20:21

1367544040539210

XLON

180

1338

09/01/2026 09:20:21

1367544040539212

XLON

66

1336

09/01/2026 09:27:21

1367544040540037

XLON

4

1336

09/01/2026 10:05:18

1367544040545512

XLON

356

1336

09/01/2026 10:07:20

1367544040545755

XLON

424

1334

09/01/2026 10:07:20

1367544040545769

XLON

121

1334

09/01/2026 10:07:26

1367544040545779

XLON

9

1334

09/01/2026 10:07:26

1367544040545780

XLON

260

1338

09/01/2026 11:01:15

1367544040551733

XLON

66

1338

09/01/2026 11:02:45

1367544040551861

XLON

823

1336

09/01/2026 11:11:07

1367544040552555

XLON

204

1334

09/01/2026 11:14:33

1367544040552735

XLON

190

1334

09/01/2026 11:14:33

1367544040552736

XLON

141

1332

09/01/2026 11:18:00

1367544040552913

XLON

154

1328

09/01/2026 11:32:45

1367544040553839

XLON

159

1334

09/01/2026 12:02:04

1367544040555609

XLON

84

1332

09/01/2026 12:13:33

1367544040557112

XLON

66

1332

09/01/2026 12:18:03

1367544040557569

XLON

125

1332

09/01/2026 12:18:04

1367544040557570

XLON

242

1336

09/01/2026 12:29:55

1367544040558491

XLON

1272

1340

09/01/2026 12:36:08

1367544040559021

XLON

700

1348

09/01/2026 13:07:35

1367544040562181

XLON

200

1348

09/01/2026 13:07:35

1367544040562187

XLON

847

1348

09/01/2026 13:10:54

1367544040562540

XLON

351

1348

09/01/2026 13:10:54

1367544040562541

XLON

1185

1348

09/01/2026 13:22:08

1367544040563729

XLON

895

1350

09/01/2026 13:36:22

1367544040565981

XLON

430

1350

09/01/2026 13:45:38

1367544040567100

XLON

150

1350

09/01/2026 13:45:38

1367544040567101

XLON

10000

1350

09/01/2026 13:49:16

1367544040567707

XLON

100

1360

09/01/2026 15:50:22

1367544040590331

XLON

214

1360

09/01/2026 16:03:38

1367544040592690

XLON

683

1360

09/01/2026 16:03:38

1367544040592693

XLON

186

1360

09/01/2026 16:03:38

1367544040592689

XLON

186

1360

09/01/2026 16:03:38

1367544040592694

XLON

12

1360

09/01/2026 16:03:38

1367544040592695

XLON

174

1360

09/01/2026 16:03:38

1367544040592696

XLON

186

1360

09/01/2026 16:03:38

1367544040592697

XLON

186

1360

09/01/2026 16:03:38

1367544040592698

XLON

186

1360

09/01/2026 16:03:38

1367544040592699

XLON

186

1360

09/01/2026 16:03:38

1367544040592700

XLON

186

1360

09/01/2026 16:03:38

1367544040592701

XLON

116

1360

09/01/2026 16:05:17

1367544040592928

XLON

 

 

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial PR) [email protected]

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUPUMGGUPQGRB

Related Shares:

CVS Group
FTSE 100 Latest
Value10,143.44
Change-6.61